About Codexis
Codexis is a company based in Redwood City (United States) founded in 2002. Codexis has raised $74.17 million across 9 funding rounds from investors including Chevron, FirstMark and Maxygen. The company has 188 employees as of December 31, 2024. Codexis offers products and services including CodeEvolver Platform and ECO Synthesis Technology. Codexis operates in a competitive market with competitors including Amyris, Syngenta, AskBio, Ginkgo Bioworks and Antheia, among others.
- Headquarter Redwood City, United States
- Employees 188 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Codexis, Inc.
-
Annual Revenue
$59.34 M (USD)-15.39as on Dec 31, 2024
-
Net Profit
-$65.28 M (USD)14.38as on Dec 31, 2024
-
EBITDA
-$50.22 M (USD)-11.91as on Dec 31, 2024
-
Total Equity Funding
$74.17 M (USD)
in 9 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Jun 20, 2019
-
Investors
Chevron
& 7 more
-
Employee Count
188
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Codexis
Codexis is a publicly listed company on the NASDAQ with ticker symbol CDXS in USA, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Codexis
Codexis offers a comprehensive portfolio of products and services, including CodeEvolver Platform and ECO Synthesis Technology.
Platform for tailoring enzyme performance in biocatalysis applications.
Technology for enzymatic processes in oligonucleotide production.
People of Codexis
Unlock access to complete
Unlock access to complete
Leadership Team
20 people
Product Management Team
8 people
Software Development Team
8 people
Scientist Team
8 people
Sales and Marketing
6 people
Finance and Accounting
5 people
Human Resources and Administration
5 people
Principal Team
3 people
Unlock access to complete
Funding Insights of Codexis
Codexis has successfully raised a total of $74.17M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Codexis
Codexis has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Chevron, FirstMark and Maxygen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Locked | Locked | Locked |
Investor details for Codexis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Codexis
Investment portfolio details for Codexis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Codexis
Detailed financials for Codexis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Codexis Comparisons
Peer comparison for Codexis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Codexis
Codexis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, AskBio, Ginkgo Bioworks and Antheia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Crop protection solutions and hybrid seeds are provided for farming.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Gene editing-based cultured ingredients are provided for agriculture.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
Detailed competitors of Codexis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Codexis
Complete news archive for Codexis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Codexis
Codexis was founded in 2002.
Codexis is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Stephen Dilly is the current CEO of Codexis.
Codexis is a funded company, having raised a total of $74.17M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Codexis is 188.
Annual revenue of Codexis is $59.34M as on Dec 31, 2024.
Codexis was founded in 2002 and is headquartered in Redwood City, United States. Operations focus on biotechnology, where the proprietary CodeEvolver platform is used to identify and engineer novel enzymes for pharmaceutical manufacturing. Additional efforts include the development of biotherapeutics and the Enzyme-Catalyzed Oligonucleotide Synthesis platform for producing RNA oligonucleotide therapeutics. These activities support drug discovery and synthesis processes in the sector.
Codexis offers CodeEvolver Platform and ECO Synthesis Technology.
Yes, Codexis is publicly traded on NASDAQ under the ticker symbol CDXS.
Codexis has 8 investors. Key investors include Chevron, FirstMark, Maxygen, Casdin Capital, and CMEA Capital.
The ticker symbol of Codexis is CDXS on NASDAQ.